Cargando…

Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer (BrC) subtype lacking effective therapeutic targets currently. The development of multi-omics databases facilities the identification of core genes for TNBC. Using TCGA-BRCA and METABRIC datasets, we identified CT83 as the mos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chen, Gao, Dan, Huo, Jinlong, Qu, Rui, Guo, Youming, Hu, Xiaochi, Luo, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190062/ https://www.ncbi.nlm.nih.gov/pubmed/34108519 http://dx.doi.org/10.1038/s41598-021-91290-4

Ejemplares similares

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Huang, Hao, et al.
Publicado: (2021)

Erratum to epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer
Publicado: (2022)

Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA
por: Shen, Shuang, et al.
Publicado: (2021)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer
por: Mendaza, Saioa, et al.
Publicado: (2020)

Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer
por: Zhai, Xiuming, et al.
Publicado: (2020)

Multiomics Topic Modeling for Breast Cancer Classification
por: Valle, Filippo, et al.
Publicado: (2022)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
por: Ensenyat-Mendez, Miquel, et al.
Publicado: (2021)

Integrative multiomics-histopathology analysis for breast cancer classification
por: Ektefaie, Yasha, et al.
Publicado: (2021)

Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses
por: Xiao, Xiao, et al.
Publicado: (2021)

Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer
por: XIAO, GUODONG, et al.
Publicado: (2022)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A
por: Liu, Cuiping, et al.
Publicado: (2020)

Integrated multiomic data analysis reveals the clinical significance of TXNIP and contributing to immune microenvironment in triple negative breast cancer
por: Gong, Han, et al.
Publicado: (2023)

A multiomics analysis of S100 protein family in breast cancer
por: Cancemi, Patrizia, et al.
Publicado: (2018)

Super-enhancer acquisition drives oncogene expression in triple negative breast cancer
por: Raisner, Ryan, et al.
Publicado: (2020)

Association between global DNA hypomethylation in leukocytes and risk of breast cancer
por: Choi, Ji-Yeob, et al.
Publicado: (2009)

Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
por: Zurlo, Giada, et al.
Publicado: (2019)

Comparing quality of life between patients undergoing trans-areola endoscopic thyroid surgery and trans-oral endoscopic thyroid surgery
por: Shen, Shuang, et al.
Publicado: (2021)

Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer
por: Ito, Yoko, et al.
Publicado: (2008)

‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’
por: Mehmood, Sabba, et al.
Publicado: (2022)

Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid
por: Chu, Yu-Hsin, et al.
Publicado: (2023)

FAM83A is a potential biomarker for breast cancer initiation
por: Marino, Natascia, et al.
Publicado: (2022)

Causal association between body mass index and autoimmune thyroiditis: evidence from Mendelian randomization
por: Huo, Jinlong, et al.
Publicado: (2023)

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016)

Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer
por: Yi, Jie, et al.
Publicado: (2016)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
por: Morrison, Chevaun D, et al.
Publicado: (2017)

Mesenchymal Cells Support the Oncogenicity and Therapeutic Response of the Hedgehog Pathway in Triple-Negative Breast Cancer
por: Reyes-Ramos, Ana M., et al.
Publicado: (2019)

SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021)

Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1
por: Ren, Yi, et al.
Publicado: (2020)

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer
por: Fang, Wentong, et al.
Publicado: (2021)

The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer
por: Wang, Wei, et al.
Publicado: (2023)

HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
por: Bartel, Courtney A., et al.
Publicado: (2017)

FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma
por: Wang, Gaoming, et al.
Publicado: (2021)

Altered cfDNA fragmentation profile in hypomethylated regions as diagnostic markers in breast cancer
por: Wang, Jun, et al.
Publicado: (2023)

Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene
por: Butler, Christopher, et al.
Publicado: (2020)

Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer
por: Zheng, Shaoquan, et al.
Publicado: (2020)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fcjp4989qbm31fo3mk60d5f2u2